167 related articles for article (PubMed ID: 33649621)
1. Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Senoo M; Tone A; Imai Y; Watanabe S; Kaneto M; Shimomura Y; Teshigawara S; Nakatou T
Acta Med Okayama; 2021 Feb; 75(1):103-107. PubMed ID: 33649621
[TBL] [Abstract][Full Text] [Related]
2. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
Paul N; Jonklaas J
Diabetes Metab Syndr; 2021; 15(1):361-363. PubMed ID: 33517150
[No Abstract] [Full Text] [Related]
3. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Ren DY; Zhang Y
Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
[TBL] [Abstract][Full Text] [Related]
5. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
[TBL] [Abstract][Full Text] [Related]
6. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin and Major Renal Outcomes in Heart Failure.
Packer M; Butler J; Zannad F; Pocock SJ; Filippatos G; Ferreira JP; Brueckmann M; Jamal W; Zeller C; Wanner C; Anker SD;
N Engl J Med; 2021 Oct; 385(16):1531-1533. PubMed ID: 34449179
[No Abstract] [Full Text] [Related]
8. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
9. Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes.
Onder CE; Gursoy K; Kuskonmaz SM; Kocer U; Culha C
J Diabetes; 2019 May; 11(5):348-350. PubMed ID: 30604507
[No Abstract] [Full Text] [Related]
10. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
Yeo SM; Park H; Paek JH; Park WY; Han S; Park SB; Jin K
Medicine (Baltimore); 2019 Jan; 98(3):e14150. PubMed ID: 30653152
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
12. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Habu M; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader R; Cowen J; Rajeev SP
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
Yasuda M; Iizuka K; Kato T; Liu Y; Takao K; Nonomura K; Mizuno M; Yabe D
J Diabetes Investig; 2020 May; 11(3):745-747. PubMed ID: 31479586
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
17. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin-induced sweet syndrome.
Mattis DM; Limova M; Mully T
Cutis; 2019 Aug; 104(2):E22-E24. PubMed ID: 31603973
[No Abstract] [Full Text] [Related]
19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
20. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
